While targeted therapies are available for most patients with BC, particularly those with estrogen receptor (ER) and/or progesterone receptor (PR) positive disease as well as those with HER2+ BC, resistance to treatment is common and novel therapeutic targets are of interest [3]. This evidence concerns the gene ERBB2 and breast cancer.